

LISA TRACKER

LISA TRACKER: Selected publications in Peer-reviewed Journals

Avouac J, Cougnaud Murail R, Goulvestre C, Dumas S, Molto A, Miceli-Richard C, Conort O, Batteux F, Allanore Y. **Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice.** Semin Arthritis Rheum. 2022 Feb;52:151951.

Francois F, Naimi L, Roblin X, Berger AE, Paul S. **Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501).** BMC Immunol. 2021 Dec 25;22(1):81.

Fernandes SR, Serrazina J, Rodrigues IC, Bernardo S, Rita Gonçalves A, Valente A, Baldaia C, Santos PM, Correia LA, Tato Marinho R. **Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease.** Eur J Gastroenterol Hepatol. 2021 Dec 1;33(12):1539-1546.

Pauwels RWM, Proietti E, van der Woude CJ, Oudijk L, Crombag MBS, Peppelenbosch MP, Grohmann U, Fuhler GM, de Vries AC. **Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease.** Inflamm Bowel Dis. 2021 Oct 20;27(11):1813-1820.

Roblin X, Genin C, Nancey S, Williet N, Veyrard P, Boschetti G, Phelip JM, Berger AE, Killian M, Waeckel L, Flourie B, Paul S. **Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels.** Inflamm Bowel Dis. 2021 Aug 18;izab158.

Marquez-Megias S, Ramon-Lopez A, Más-Serrano P, Diaz-Gonzalez M, Candela-Boix MR, Nalda-Molina R. **Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease.** Pharmaceutics. 2021 Aug 12;13(8):1244.

Rusche H, Marrani E, Real-Fernandez F, Ponti R, Terzani F, Maccora I, Monasson O, Mastrolia MV, Peroni E, Pagnini I, Cimaz R, Papini AM, Simonini G, Rovero P. **A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis.** Sci Rep. 2021 Aug 12;11(1):16393.

Konecki C, Feliu C, Cazaubon Y, Giusti D, Tonye-Libyh M, Brixi H, Cadiot G, Biron A, Djerada Z. **External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab.** Pharmaceutics. 2021 Aug 3;13(8):1191.

Giraud M, Cathébras P, Roblin X, Thibaudin D, Lamure S, Mariat C, Paul S, Killian M. **Immunomonitoring du rituximab appliqué aux maladies auto-immunes : une aide pour la pratique clinique ? [Rituximab**

immunomonitoring in autoimmune diseases: a support tool in clinical practice?]. Rev Med Interne. 2021 Jun;42(6):384-391.

West TA, Sam M, Toong C. **Comparison of three commercially available ELISA assays for anti-infliximab antibodies.** Pathology. 2021 Jun;53(4):508-514.

Papamichael K, Clarke WT, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. **Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases.** Clin Gastroenterol Hepatol. 2021 Apr;19(4):839-841.e2.

Villemonteix J, Guérin-El Khourouj V, Hugot JP, Giardini C, Carcelain G, Martinez-Vinson C. **Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases.** Biologicals. 2021 Apr;70:17-21.

Wadhwa M, Bird C, Atkinson E, Cludts I, Rigsby P. **The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring.** Front Immunol. 2021 Apr 15;12:636420.

Bravo F, Macpherson JA, Slack E, Patuto N, Cahenzli J, McCoy KD, Macpherson AJ, Juillerat P; SATICC (Sensitivity to Anti-TNF Inhibition in Crohn's disease and ulcerative Colitis) study group. **Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up.** Clin Transl Gastroenterol. 2021 Feb 15;12(2):e00298.

Al Tabaa O, Etcheto A, Dumas S, Batteux F, Goulvestre C, Moltó A, Miceli-Richard C, Dougados M. **Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center.** Eur J Clin Pharmacol. 2021 Jan;77(1):25-33.

Sam MJ, Connor SJ, Ng WW, Toong CM. **Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies.** Ther Drug Monit. 2020 Dec;42(6):821-828.

Rocha C, Lago P, Fernandes S, Correia L, Portela F, Vieira AI, Patita M, Arroja B, Ministro P, Alves C, Dias CC, Magro F. **Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays.** Therap Adv Gastroenterol. 2020 Nov 18;13:1756284820965790.

Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ and Van de Casteele N. **Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.** Clin Transl Sci. 2020; 13, 743–751.

Pugliese D, Guidi L, Privitera G, Bertani L, Tolusso B, Papparella LG, Maltinti S, Di Mario C, Onali S, Ceccarelli L, Rapaccini GL, Scaldaferri F, Gremese E, Gasbarrini A, Costa F, Armuzzi A. **Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients** Expert Opin Biol Ther. 2020 Oct 31;1-8.

Hässler S,Bachelet D, Duhaze J, Szely N, Gleizes A, Hacein-Bey Abina S, Aktas O, Auer M, Avouac J, Birchler M, Bouhnik Y, Brocq O, Buck-Martin D, Cadiot G, Carbonnel F, Chowers Y, Comabella M, Derfuss T, De Vries

N, Donnellan N, Doukani A, Guger M, Hartung HP, Kubala Havrdova E, Hemmer B, Huizinga T, Ingenhoven K, Hyldgaard-Jensen PE, Jury EC, Khalil M, Kieseier B, Laurén A, Lindberg R, Loercher A, Maggi E, Manson J, Mauri C, Oumoussa BM, Montalban X, Nachury M, Nytrova P, Richez C, Ryner M, Sellebjerg F, Sievers C, Sikkema D, Soubrier M, Tourdot S, Trang C, Vultaggio A, Warnke C, Spindeldreher S, Dönnies P, Hickling TP, Hincelin Mery A, Allez M, Deisenhammer F, Fogdell-Hahn A, Mariette X, Pallardy M, Broët P, ABIRISK consortium **Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium** PLoS Med. 2020 Oct 30;17(10):e1003348

Dave MP, Dherai AJ, Desai DC, Keny BG, Shetty DN, Kulkarni S, Peddy K, Ashavaid TF. **Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit** Indian J Gastroenterol. 2020 Oct 29.

Vaughn BP, Yarur AJ, Graziano E, Campbell JP, Bhattacharya A, Lee JY, Gheysens K, Papamichael K, Osterman MT, Cheifetz AS, Cross RK. **Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease in Clinical Remission after Adalimumab Dose Intensification.** J Clin Med. 2020 Sep 28;9(10):E3142

Flanagan E, Gibson PR, Wright EK, Moore GT, Sparrow MP, Connell W, Kamm MA, Begun , Christensen B, De Cruz P, Shelton E, Dowling D, Andrews JM, Brown SJ, Niewiadomski O, Ward MG, Rosella O, Rosella G, Kiburg KV, Ross AL, Bell SJ, PICCOLO Study Group. **Infliximab, Adalimumab and Vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure** Aliment Pharmacol Ther. 2020 Sep 27.

Paul S, Williet N, Nancey S, Veyrard P, Boschetti G, Phelip JM, Flourie B, Roblin X **No Difference of Adalimumab Pharmacokinetics when dosed at 40mg Every Week or 80mg Every Other Week in IBD Patients in Clinical Remission after Adalimumab Dose Intensification** Dig Dis Sci . 2020 Sep 16

Al Taaba O, Etcheto A, Dumas S, Batteux F, Goulvestre C, Molto A, Miceli-Richard C, Dougados M. **Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center** Eur J Clin Pharmacol. 2020 Sep 4.

Dave MB, Dherai AJ, Desai DC, Mould DR, Ashavaid TF. **Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.** Eur J Clin Pharmacol. 2020 Sep 4.

Lambrescak E, Vaysse T, Carbonnel F, Rachas A, Allez A, Ungar B, Gleizes A, Hacein-Bey S, Roblin X, Kopylov U. **Duration of combination therapy and risk of treatment failure in patients with inflammatory bowel disease** Clin Res Hepatol Gastroenterol. 2020 Sep 3

Samaan MA, Cunningham G, Tamilarasan AG, Beltran L, Pavlidis P, Ray S, Mawdsley J, Anderson SH, Sanderson JD, Arkir Z, Irving PM **Therapeutic Thresholds for Golimumab Serum Concentrations During Induction And Maintenance Therapy in Ulcerative Colitis: Results from the GO-LEVEL Study** Aliment Pharmacol Ther . 2020 Jul;52(2):292-302.

Marotte H, Rinaudo-Gaujous M, Petiet C, Fautrel B, Paul S **Tapering Without Relapse in Rheumatoid Arthritis Patients With High TNF Blocker Concentrations: Data from STRASS Study** Ann Rheum Dis . 2020 Jul;79(7):e81.

Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Castele N **Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis** Clin Transl Sci. 2020 Feb 26.

Lauret A, Moltó A, Abitbol V, Gutermann L, Conort O, Chast F, Goulvestre C, Le Jeune C, Chaussade S, Roux C, Batteux F, Dougados M, Allanore Y, Avouac J **Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice.** Semin Arthritis Rheum. 2020 Feb 19.

Roblin X, Williet N, Boschetti G, Phelip JM, Del Tedesco E, Berger AE, Vedrines P, Duru G, Peyrin-Biroulet L, Nancey S, Flourie B, Paul S **Addition of Azathioprine to the Switch of anti-TNF in Patients With IBD in Clinical Relapse With Undetectable anti-TNF Trough Levels and Antidrug Antibodies: A Prospective Randomised Trial** Gut. 2020 Jan 24.

Neveu B, Kunst A, Prosser C, Robitaille R **An in Vitro Comparison of Four Different Immunoassays for the Monitoring of Infliximab Biosimilars Drug Levels** Clin Biochem. 2020 Jan 23.

Petitdidier N, Beaugerie L, Carbonnel F, Bourrier A, Treton X, Sylvie Rajca S, Georgia Malamut G, Abitbol V, Allez M, Pelletier AL, Marthey L, Jouet P, Benamouzig R, Amiot X, Bouhnik Y, Amiot A, **Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease** Clin Res Hepatol Gastroenterol. 2020 Jan 7

Valido A, Silva-Dinis J, Saavedra M, Iria I, Gonçalves J, Lopes JP, Fonseca JE. **Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.** Acta Reumatol Port. 2019 Nov 22.

Boyer-Suavet S, Andreani M, Lateb M, Savenkoff B, Brglez V, Benzaken S, Bernard G, Nachman PH, Esnault V, Seitz-Polski B. **Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated with Rituximab** Front Immunol. 2019; 10: 3069

Grossi V, Infantino M, Manfredi M, Basile U, Gulli F, Marino M, Li Gobbi F, Damiani A, Atzeni F, Benucci M. **Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports.** Clin Chem Lab Med. 2019 Oct 30.

Clarke WT, Papamichael K, Vande Castele N, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. **Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study.** Inflamm Bowel Dis. 2019 Oct 18;25(11):e143-e145.

Painchart C, Brabant S, Duveau N, Nachury M, Desreumaux P, Branche J, Gérard R, Prevost CLD, Wills P, Lambin T, Boualit M, Labalette M, Pariente B. **Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.** Dig Dis Sci. 2019 Oct 10.

Combiér A, Nocturne G, Henry J, Belkhir R, Pavy S, Le Tiec C, Descamps E, Seror R, Mariette X. **Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.** Rheumatology (Oxford). 2019 Oct 9.

Guidi L, Pugliese D, Tonucci TP, Bertani L, Costa F, Privitera G, Toluoso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A. **Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.** United European Gastroenterol J. 2019 Nov;7(9):1189-1197. Epub 2019 Sep 3.

Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, Ticchioni M, Rosenthal A, Benzaken S, Bernard G, Lambeau G, Ronco P, Esnault VLM. **High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.** Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1173-1182.

Paul S, Roblin X. **Letter: immunogenicity of anti-TNF in elderly IBD patients.** Aliment Pharmacol Ther. 2019 Aug;50(3):336.

Fernandes SR, Bernardo S, Simões C, Gonçalves AR, Valente A, Baldaia C, Moura Santos P, Correia LA, Tato Marinho R. **Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.** Inflamm Bowel Dis. 2019 Jun 27.

Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG. **Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis.** J Crohns Colitis. 2019 May 15.

Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, Nachman P, Esnault V, Seitz-Polski B. **Rituximab bioavailability in primary membranous nephropathy.** Nephrol Dial Transplant. 2019 Mar 30.

Ungar B, Ben-Shatah Z, Ben-Haim G, Yavzori M, Picard O, Fudim E, Kopylov U, Veyrard P, Del Tedesco É, Paul S, Eliakim R, Ben-Horin S, Roblin X. **Infliximab therapy intensification upon loss of response: Is there an optimal trough level?** Dig Liver Dis. 2019 Mar 5.

Soufflet N, Boschetti G, Roblin X, Cuercq C, Williet N, Charlois AL, Duclaux-Loras R, Danion P, Mialon A, Faure M, Paul S, Flourie B, Nancey S. **Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease.** Clin Gastroenterol Hepatol. 2019 Mar 6.

Al-Bawardy B, Ramos GP, Willrich MAV, et al. **Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease.** Inflamm Bowel Dis. 2019;25(3):580-586.

Berger AE, Duru G, de Vries A, Marini JC, Aoucheta D, Cornillie F, Nancey S, Detrez I, Gils A, Roblin X, Paul S. **Comparison of immunoassays for measuring serum levels of golimumab and antibodies against golimumab in ulcerative colitis: a retrospective observational study.** Ther Drug Monit. 2019 Feb 26.

Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, Danese S, Baumann C, Peyrin-Biroulet L. **Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.** J Crohns Colitis. 2019 Jan 29.

Ilias A, Szanto K, Gonczi L, Kurti Z, Golovics PA, Farkas K, Schafer E, Szepes Z, Szalay B, Vincze A, Szamosi T, Molnar T, Lakatos PL. **Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.** Clin Gastroenterol Hepatol. 2019 Jan 7.

Attar A, Duru G, Roblin X, Savarieau B, Brunel P, Lamure M, Peyrin-Biroulet L. **Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study.** Dig Liver Dis. 2019 Jan;51(1):112-119.

Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X; ABIRISK Consortium. **Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.** Semin Arthritis Rheum. 2018 Oct 12. pii: S0049-0172(18)30176-8.

Jentzer A, -Emmanuelle Berger A, Labetoulle R, Haccourt A, Roblin X, Paul S. **Short Communication: Evaluation of infliximab and anti-infliximab LISA-TRACKER immunoassays for the therapeutic drug monitoring of SB2 infliximab biosimilar.** Ther Drug Monit. 2018 Sep 21.

Poullenot F, Nivet D, Paul S, Riviere P, Roblin X, Laharie D. **Severe endoscopic lesions are not associated with more infliximab fecal loss in acute severe ulcerative colitis.** Dig Liver Dis. 2018 Jul 10.

Nasser Y, Labetoulle R, Harzallah I, Berger AE, Roblin X, Paul S. **Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.** Dig Dis Sci. 2018 Jun 9.

Dutzer D, Nasser Y, Berger AE, Roblin X, Paul S. **Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients.** Aliment Pharmacol Ther. 2018 Jun;47(11):1571-1573.

Guidi L, Pugliese D, Panici Tonucci T, Berrino A, Tolusso B, Basile M, Cantoro L, Balestrieri P, Civitelli F, Bertani L, Marzo M, Felice C, Gremese E, Costa F, Viola F, Cicala M, Kohn A, Gasbarrini A, Rapaccini GL, Ruggeri M, Armuzzi A. **Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study.** J Crohns Colitis. 2018 May 31.

Paul S, Williet N, Di Bernado T, Berger AE, Boschetti G, Filippi J, Del Tedesco E, Nancey S, Flourie B, Roblin X. **Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.** J Crohns Colitis. 2018 May 31.

Toro-Montecinos M, Ballescá F, Ferrandiz C, Teniente-Serra A, Martinez-Caceres E, Carrascosa JM1. **Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks.** J Dermatolog Treat. 2018 May 10:1-5.

Ben-Horin S, Ungar B, Kopylov U, Lahat A, Yavzori M, Fudim E, Picard O, Peled Y, Eliakim R, Del Tedesco E, Paul S, Roblin X. **Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.** Aliment Pharmacol Ther. 2018 Apr;47(8):1117-1125.

Labetoulle R, Roblin X, Paul S. **Prolonged Persistence of Adalimumab Transferred From Mother to Infant During Pregnancy.** Ann Intern Med. 2018 Mar 6.

Bastida C, Ruiz-Esquivel V, Pascal M, de Vries Schultink AHM, Yagüe J, Sanmartí R, Huitema ADR, Soy D. **Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.** Br J Clin Pharmacol. 2018 Jan 4.

Yacoub W, Williet N, Pouillon L, Di-Bernado T, De Carvalho Bittencourt M, Nancey S, Lopez A, Paul S, Zallot, Roblin X, Peyrin-Biroulet L. **Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.** Aliment Pharmacol Ther. 2018 Jan 31.

Gouynou C, Pouillon L, Rousseau H, Zallot C, Baumann C, Peyrin-Biroulet L. **Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation.** Gut. 2018 Jan 13.

Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F. **Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases.** Biologics: Targets and Therapy 2018;12 37–41

Einarsson JT, Evert M, Geborek P, Saxne T, Lundgren M, Kapetanovic MC. **Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.** Clin Rheumatol. 2017 Dec;36(12):2743-2750.

Avouac J, Moltó A, Abitbol V, Etcheto A, Salcion A, Gutermann L, Klotz C, Elhai M, Cohen P, Soret PA, Morin F, Conort O, Chast F, Goulvestre C, Jeunne CL, Chaussade S, Kahan A, Roux C, Allanore Y, Dougados M. **Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France.** Semin Arthritis Rheum. 2017 Oct 5.

Fay S, Ungar B, Paul S, Levartovsky A, Yavzori M, Fudim E, Picard O, Eliakim R, Ben-Horin S, Roblin X, Kopylov U. **The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors.** Inflamm Bowel Dis. 2017 Aug 22.

Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S. **Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.** Inflamm Bowel Dis. 2017 Sep 22.

Gonczi L, Kurti Z, Rutka M, Vegh Z, Farkas K, Lovasz BD, Golovics PA, Gecse KB, Szalay B, Molnar T, Lakatos PL. **Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.** BMC Gastroenterol. 2017 Aug 8;17(1):97

Johnston EL, Warner BD, Digby-Bell JL, Unsworth N, Anderson S, Sanderson J D, Arkir Z, Irving PM. **Utilisation of anti-TNF levels in a UK tertiary IBD centre.** Frontline Gastroenterol. 2017 Jul;8(3):189-195.

Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM. **Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.** Aliment Pharmacol Ther. 2017 Jul;46(2):150-161.

Mota F, Neves E, Oliveira JC, Selores M, Torres T. **Importance of immunogenicity testing for cost-effective management of psoriasis patients treated with adalimumab.** Acta Dermatovenereol Alp Pannonica Adriat. 2017 Jun;26(2):33-35.

Bor R, Farkas K, Fábíán A, Bálint A, Milassin Á, Rutka M, Matuz M, Nagy F, Szepes Z, Molnár T. **Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease.** PLoS One. 2017 Mar 31;12(3):e0172916.

Dénarié D, Rinaudo-Gaujous M, Thomas T, Paul S, Marotte H. **Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab.** Mediators Inflamm. 2017 Epub 2017 Mar 2.

Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-Biroulet L, Paul S. **Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.** Inflamm Bowel Dis. 2017 Jan;23(1):126-132.

Martelli L, Olivera P, Roblin X, Attar A3, Peyrin-Biroulet L4. **Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.** J Gastroenterol. 2017 Jan;52(1):19-25.

Ungar B, Kopylov U, Engel T, Yavzori M, Fudim E, Picard O, Lang A, Williet N, Paul S, Chowers Y, Bar-Gil Shitrit A, Eliakim A, Ben-Horin A, Roblin X. **Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.** Aliment Pharmacol Ther. 2017 Jan;45(2):276-282.

Williet N, Boschetti G, Fovet M, Di Bernado T, Claudez P, Del Tedesco E, Jarlot C, Rinaldi L, Berger A, Phelip JM, Flourie B, Nancey S, Paul S, Roblin X. **Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases With Need for Additional Doses Within 6 months.** Clin Gastroenterol Hepatol. 2016 Nov 24.

Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztanyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Papp M, Patai Á, Salamon Á, Tóth GT, Vincze Á, Biro E, Lovasz BD, Kurti Z, Szepes Z, Molnár T, Lakatos PL. **Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?** J Crohns Colitis. 2016 Nov 12.

Vincent FB, Pavy S, Krzysiek R, Lequerré T, Sellam J, Taoufik Y, Mariette X, Miceli-Richard C. **Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.** Joint Bone Spine. 2016 Oct;83(5):595-7.

Lee MW, Connor S, Ng W, Toong CM. **Compari**

son of infliximab drug measurement across three commercially available ELISA kits. Pathology. 2016 Aug 23.

Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, Manfredi M, Parisi S, Fusaro E, Batticciotto A, Sarzi-Putini P, Atzeni F, Meacci F. **Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.** Immunol Res. 2016 Jul 23.

Benucci M, Meacci F, Grossi V, Infantino M, Manfredi M, Bellio E, Bellio V, Li Gobbi F, Bazzichi L, Moscato P, Caputo D, Saviola G, Talotta R, Sarzi-Putini P, Atzeni F. **Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab.** Biologics. 2016 Mar 11;10:53-8.

Gecse KB, Lovász BD, Farkas K, Banai J, Bene L, Gasztanyi B, Golovics PA, Kristóf T, Lakatos L, Csontos ÁA, Juhász M, Nagy F, Palatka K, Papp M, Patai Á, Lakner L, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Szalay B, Molnár T, Lakatos PL. **Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.** J Crohns Colitis. 2016 Feb;10(2):133-40.

Zufferey P, Perreau M, So A. **High level of anti-drug antibodies after intra-articular injection of anti-TNF.** Rheumatology (Oxford). 2015 Dec;54(12):2291-2

Coutzac C, Chapuis J, Poullenot F, Chabrun E, Capdepon M, Blanco P, Laharie D. **Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.** J Crohns Colitis. 2015 Nov;9(11):982-7.

Schmitz EM, van de Kerkhof D, Hamann D, van Dongen JL, Kuijper PH, Brunsveld L, Scharnhorst V, Broeren MA. **Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.** Clin Chem Lab Med. 2015 Nov 20.

Roblin X Attar A, Lamure M, Savarieau B, Brunel P, Duru G, Peyrin-Biroulet L. **Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab.** Journal of Market Access & Health Policy, [S.l.], v. 3, oct. 2015.

Paul S, Roblin X, Peyrin-Biroulet L. **Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease.** Aliment Pharmacol Ther. 2015 Oct;42(7):939-40.

Roblin X, Paul S. **Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease.** Aliment Pharmacol Ther. 2015 Jul;42(2):240.

Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B, Eliakim R, Del Tedesco E, Paul S, Roblin X. **Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.** Aliment Pharmacol Ther. 2015 Aug;42(3):356-64.

Rinaudo-Gaujous M, Roblin X, Marotte H, Paul S. **The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.** Ann Rheum Dis. 2015 Aug;74(8):e40.

Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S. **Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.** J Crohns Colitis. 2015 Jul;9(7):525-31.

Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S. **Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.** Clin Gastroenterol Hepatol. 2014 Jan;12(1):80-84.e2.

Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S. **Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.** Am J Gastroenterol. 2014 Aug;109(8):1250-6.

Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. **Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.** Inflamm Bowel Dis. 2013 Nov;19(12):2568-76.

Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. **Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.** Br J Dermatol. 2013 Aug;169(2):306-13.

Daïen CI, Daïen V, Parussini E, Dupuy AM, Combe B, Morel J. **Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study.** J Rheumatol. 2012 Aug;39(8):1533-8.



14 rue Ambroise Croizat
CS 90136 CROISSY
BEAUBOURG
77435 MARNE LA VALLEE
CX2
France

Tel : +33 (0)1 64 62 10 12
Fax : +33 (0)1 64 62 09 66

E-mail : support@theradiag.com
Internet : www.theradiag.com